United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn ...

Insmed (NASDAQ:INSM) announced Tuesday that TPIP, its experimental therapy for pulmonary arterial hypertension, succeeded in ...

United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Click ...

United Therapeutics UTHR shares soared 3.5% in the last trading session to close at $286.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares.United Therapeutics’ Q4 earnings ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. United Therapeutics beat analysts’ revenue ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced ...

Morningstar brands and products Company Portfolio ...